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Abstract 
In the present study, the synthesized benzopyran isoxazolines and isoxazoles were evaluated for antibacterial 
activity by Agar well diffusion method against multi drug resistance (MDR) clinical isolates of five bacterial 
strains.i.e., Staphylococcus sp. (2413), Enterococcus sp. (2449), and Escherichia sp. (2461), Acinetobacter sp. 
(2457) and Serratia sp (2442). MIC (Minimum inhibitory concentration) and MBC (Minimum bactericidal 
concentration) of the potent derivatives were calculated and tabulated. A partial structure activity relationship 
(SAR) was done on the basis of microbial inhibition data. Compounds 3, 6, 8, 9, 11, 14 and 20 were the most 
promising antibacterial molecule. Compound 3, the precursor of isoxazole / isoxazoline found to be most 
active antibacterial candidate as well as bactericidal too.  
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1.0 Introduction 
Over the preceding years in our understanding of human disease we have made a rapid progress in the field 
of antibiotics. Getting a novel antibiotic seems to be hard all these days. The cause behind it may be more 
often bacteria are exposed to a certain antibiotic, the more opportunities they have to evolve resistance to 
combat it. This furnishes antibiotics, the authentication of modern medicine, nearly ineffective against 
‘nightmare bacteria’. The resistance rates in the ‘90s were at 10 to 15 percent while, now it’s up to 60 percent 
in hospitals.1 Therefore, there is a pressing need of communal feat to address the menace and simultaneously 
preface of new drug candidates to scrap these pandemic infections. An additional major concern for antibiotic 
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resistance is that it has not been represented appropriately across the world. Statistical data shows that in low- 
and middle-income countries, where antibiotic resistance is a serious problem but rarely the focus of policy 
solutions.2  The resistance of E.coli is rising day by day in many world regions, according to resistance map.3 
India has the highest rates of resistance to all the antibiotics as compared to all other countries throughout 
world; E. coli strains are more than 80 percent resistant to different classes of drugs, which clearly indicates 
treatment options are becoming increasingly limited day by day.4 Hence, in view of the latest trend of bacterial 
resistant the screening of the synthesised compounds were conducted against ampicillin and gentamicin 
resistant Escherichia coli and Staphylococcus aureus; ciprofloxacin resistant Serratias pecies;imepenem resistant 
Acinetobacter and Enterococcus (MDR) species.  
Flavones/chromenes/Benzopyran are reputed for antibacterial activity from ancient days both synthetic as well 
as natural origin. Literature says flavones having benzimidazole scaffolds has good antibacterial property 
against Staphylococcus aureus (Fig. 1).5  
 
Fig.1. Chromene with imidazole having antibacterial activity against Staphylococcus aureus 
Natural flavones such as semiglabrin, pseudosemiglabrin, apollinine, lanceolatin A, crysin isolated from 
Tephrosia nubica were very effective against different strains of bacteria viz Penicillium funiculus, Fusarium 
moniliforumspergillus, Aspergillus niger etc (Fig.2).6 
 
Fig.2. Some examples of natural chromene as antibacterial agents 
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Isoxazoles and isoxazolines are ubiquitously found in nature as well as synthesized from various precursors.7 It 
has been used as FDA approved drugs in pharmaceuticals, such as antibiotics (cloxacillin, dicloxacillin, 
cycloserine, etc).8 chromenes fused with these scaffold are also known as antimicrobial agents when we look at 
the literature precence.9 But Chromene isoxazoles/ isoxazolines having halogen substituents (monochloro, 
geminal chlorine or vicinal chlorine) was never reported earlier as any antibacterial agents. It could be used to 
enhance the activity as efficiency of substrate target binding ameliorates.10 Shah and co-workers has reported 
the presence of chlorine accentuates the antibacterial properties of isoxazole and isoxazoline.11 In this report 
we have focused on antimicrobial evaluation of our synthesized dichloro chromene isoxazoles. With the 
skilfulness in the field of medicinal chemistry, 12 we have synthesized different chromene isoxazoles and the 
isoxazolines in our previous paper.13 This is an extension of that paper where we have attempted a biological 
study (antimicrobial) of those synthesized compounds and analysed there efficacy with reference to standard 
drugs like Tetracycline and Gentamicin. 
2.0 Materials and methods 
2.01. Chemistry 
1H and 13C NMR spectra were recorded on 400 and 500 MHz spectrometers with TMS as the internal standard. 
Chemical shifts are expressed in parts per million (δ ppm). Silica gel coated aluminium plates were used for 
TLC. The products were purified by column chromatography on silica gel (60-120/100-200/230-400 mesh) 
using petroleum ether–ethyl acetate as the eluent to obtain the pure products. Reagents used were mostly 
purchased from Sigma Aldrich if not mentioned otherwise. 
2.02. Biology  
2.02.1. Microorganisms and culture media 
 The following five MDR bacterial clinical isolates were used in this study: Staphylococcus aureus (2413), 
Enterococcus sp. (2449), Serratia sp. (2442), Acinetobacter sp. (2457) and Escherichia coli (2461). All the strains 
were obtained from Dr. Kumardeep Dutta Choudhary, Department of Medical Oncology, Rajiv Gandhi Cancer 
Research Institute, Delhi, India with their respective antibiotic resistance profiles (provided in below table). All 
bacterial strains were grown on 5% nutrient broth (NB). Following the initial incubation, organisms were 
suspended in 15ml of NB and optical density readings were compared to a 0.5 McFarland standard. For the 
MIC determination, bacterial suspension of 5×106 colony-forming units (cfu) ml was employed [ CLSI, 
Performance Standards for Antimicrobial Disk Susceptibility Tests, Approved Standard, 7th ed., CLSI document 
M02-A11.] 
2.02.2. Agar well diffusion assay 
Antibacterial activity of the synthesised compounds was determined by agar well diffusion method by 
previously described method by Rosa et al. Briefly, nutrient agar plates were inoculated with 0.1 mL of each 
organism (1x108 CFU/mL). Subsequently, wells of 6 mm size were bored into the nutrient agar set plates 
containing the bacterial culture and treated with 40 μL of samples prepared from a stock solution of 1mg/mL. 
in 2% DMSO solution. The plates were incubated at 37°C for 24 h. Standard antibiotic disc of tetracycline, 
gentamycin (30 µg) and 2% DMSO solution was taken as positive and negative as control.  Assays were carried 
out by triplicate and the antimicrobial activity was expressed as the mean diameter of inhibition zones (mm) 
with standard deviation. 
2.02.3. Determination of Minimum Inhibitory concentration (MIC) and Minimum Bactericidal 
concentration (MBC) 
MIC was determined by microdilution method described by Weigand et al. Briefly, the cultures were diluted in 
Mueller-Hinton broth at a density of 0.5 McFarland turbidity. 0.5 mL of a bacterial suspension (5×106 CFU/mL) 
To Chemistry Journal Vol 3 (2019) ISSN: 2581-7507                                   http://purkh.com/index.php/tochem 
59 
was added to 4.5 mL of susceptibility test broth containing diluted compound solution, prepared by serial 
two-fold dilution from the stock solution (1mg/mL). A number of wells were reserved in each plate for control 
of sterility (no inoculum was added), inoculum viability (no sample solution was added) and DMSO inhibitory 
effect. The plates were then incubated for 24 h at 37° C. After 24 h of incubation, the absorbance was read at 
570 nm in ELISA reader. MIC of tetracycline was used as standard determined in parallel experiment for 
comparison. Assays were carried out by triplicate   and MIC was considered as the lowest concentration of the 
sample that prevented visible growth.  
2.02.4. Determination of Minimum Bactericidal concentration (MBC) 
The MBC assays were performed as described by Goda et al. Briefly, the wells which showed complete absence 
of bacterial growth were identified and aliquots (10µl) of each well were transferred to Muller Hilton agar 
plates and incubated at 37ºC for 24 hrs. Experiments were carried out by triplicate and the complete absence 
of growth was considered as the minimum bactericidal concentration. 
2.02.5. Statistical Analysis 
All experiments were carried out in triplicates and statistical analysis was carried out using Graph Pad Prism 
version 4.00 for Windows, GraphPad Software, San Diego California USA. Data are presented as Mean±SD. 
2.02.6. Graphical Analysis 
All experiments were analysed using “Microsoft Office Excel 2007”, column charts to analyse the antimicrobial 
evaluation. 
2.03. Result and Discussion: 
2.03.1. Chemistry 
For the synthesis, our strategy began from 4-chloro-6-formyl benzopyran II synthesis. This was derived from 
chromanone I which was easily achieved from resorcinol by acylating it (Friedel Craft’s reaction) and then 
condensation with substituted ketones (Aldol condensation). Then the 7-hydroxy benzopyran-4-one so 
formed on alkylation yield 7-alkoxy-2,2-dimethylchroman-4-one I. By treating I with Vilsmeier-Haak reagent, 
we could affect formylation at C-6 as well as chlorination at C-4 of the benzopyran (Scheme-1).  
 
Scheme 1: Synthesis of 4-chloro-6-formyl benzopyran 
Formylated benzopyran IIa was converted to corresponding oxime IIIa by treating with hydroxyl amine 
hydrochloride and pyridine (scheme 3). Benzopyran aldoxime derivative IIIa thus obtained was treated in DMF 
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with 4-CN-phenyl acetylene as dienophile and NCS in the presence of triethylamine at room temperature to 
obtain desired benzopyran isoxazole compound IVa in 6 hrs at room temperature (scheme 2).  
                               
Scheme 2: Synthesis of chromene isoxazole hybrid from chromene carbaldehyde 
While characterizing IVa, 1H spectroscopy the proton shifts for dimethyl appeared at C2 (  1.72), methoxy 
signal appeared at  4.00, isoxazole proton signal appeared at  7.06. All the aromatic proton was clear (see 
supporting). Dimethyl signal appeared like a hump instead of sharp peak (Fig. 3). When 13C spectra was 
analysed we achieved a quaternary carbon (carbonyl carbon C4) at  178.61 (fig.4) instead of chlorine (  
125.99) and a loss of olefin shift at 125.35 in chlorochromene (see supporting).   
 
Fig.3: 1H NMR spectra of Iva 
After the characterization of the final compound we have synthesized 16 derivatives. Structures are given in 
Table1 (05-20). A detailed discussion of all the synthesized compounds was done in the previous paper.13 
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2.03.2. Biology  
2.03.2.1. Antibacterial activity 
In order to test the antibacterial property of the synthesised compounds, agar well diffusion assay was 
performed. The antimicrobial drugs, tetracycline and gentamycine, were used as positive controls. The 
antibacterial activity of all the compounds were evaluated in-vitro by measuring the inhibition zone (in mm) 
for growth inhibitory effect against Multi drug resistance (MDR) clinical isolates of five bacterial strains; two 
Gram-positive bacteria (Staphylococcus aureus (2413), Enterococcus sp. (2449),) and three Gram-negative 
bacteria (Escherichia coli (2461), Acinetobacter sp. (2457) and Serratia sp (2442).) The antibacterial activities 
were tested at concentrations of 1mg/ml in 2% DMSO solution. The bacterial cultures were inoculated and 
incubated according to the described protocol of the experimental section.   
All the synthesized molecules and their precursors were analysed for an antibacterial assay. The experimental 
results of this in vitro antibacterial evaluation are summarized in Tables 1. 
(Table 1) In vitro antibacterial activity of the benzopyran fused isoxazole and isoxazoline derivatives against 
different bacterial strains 
S. 
No 
Name of the compound S. aureus Serratia sp S. 
enteroccou
s 
Acinetobact
or 
E.coli 
01 
 
12.236±0.20 10.165±0.28 7.126±0.13 9.105±0.28 7.160±0.38 
02 
 
10.166±0.20 6.330±0.13 5.166±0.28 6.166±0.26 5.166±0.28 
03 
 
17.166±0.28 14.83±0.62 13±0.50 11.146±0.22 13.66±0.47 
04 
 
10.166±0.28 9.16±0.23 7.166±0.28 7.160±0.36 8.176±0.28 
05 
 
8.16±0.23 14.83±0.62 10.16±0.23 8.56±0.18 13.66±0.47 
06 
 
10.48±0.54 12.50±0.40 14.83±0.62 16.548±0.23 12.83±0.23 
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S. 
No 
Name of the compound S. aureus Serratia sp S. 
enteroccou
s 
Acinetobact
or 
E.coli 
07 
 
8.16±0.23 8.33±0.47 9.16±0.23 13.501±0.23 11.50±0.40 
08 
 
13.547±0.20 12.501±0.40 12.832±0.2
3 
15.657±0.51 12.010±0.0
0 
09 
 
11.475±0.10 10.60±0.40 12.357±0.3
0 
11.573±0.21 09.001±0.0
6 
10 
 
7.16±0.13 6.33±0.46 6.16±0.23 03.501±0.29 07.50±0.40 
11 
 
14.735±0.20 11.60±0.40 10.354±0.3
6 
12.573±0.22 07.058±0.0
6 
12 
 
07.847±0.23 08.501±0.46 11.830±0.1
3 
11.657±0.51 10.010±0.0
0 
13 
 
12. 745±0. 01 13.60±0.15 12.057±0.2
0 
14.573±0.16 10.001±0.2
5 
14 
 
14.847±0.15 08.500±0.43 10.010±0.0
3 
11.657±0.51 12.830±0.0
1 
 
15 
 
12.05±0.30 11.50±0.47 11.83±0.62 12.58±0.23 10.83±0.02 
16 
 
8.33±0.47 9.33±0.40 8.16±0.23 10.33±0.38 6.33±0.47 
17 
 
10.287±0.05 09.500±0.40 11.010±0.0
2 
11.657±0.48 11.830±0.0
8 
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S. 
No 
Name of the compound S. aureus Serratia sp S. 
enteroccou
s 
Acinetobact
or 
E.coli 
18 
 
10.166±0.26 09.330±0.13 11.166±0.2
8 
8.166±0.20 07.166±0.1
8 
19 
 
10.62±0.43 09.84±0.23 8.33±0.47 07.44±0.15 5.33±0.31 
20 
 
12.66±0.63 10.66±0.23 8.33±0.47 14.66±0.15 7.33±0.28 
 Tetracycline 16.56±0.58 17.42±0.58 15.71±0.58 14.73±0.35 18.85±0.53 
 Gentamicin 15.76±0.58 17.23±0.58 14.68±0.35 15.71±0.58 18.79±0.58 
N.B. Antimicrobial activity expressed as diameter of zone of inhibition in mm including 6 mm as diameter of 
the well. Value (mm) ±S.D of three replicates. All compounds were tested at 1mg/mL concentration. 30 µg 
Tetracycline and Gentamycin discs were used as positive control. 2% DMSO solution was used as negative 
control, 
2.03.2.2. Data Analysis 
We have made a comparison study of our synthesised compounds and their precursors with the help of 
“Microsoft Office excel 2007” for a transparent analysis against five different strains of bacteria. 
The obtained result revealed that among the tested compounds 1-20 only 3, 8, 11, 13 and 14 showed good 
inhibition against Staphylococcus aureus. As a general study the formylated chromene 3 which is a precursor 
with no substitution at any position shows very good inhibitory effect (17.166±0.28), even more than the 
standard drug we have taken (16.56±0.58 &15.76±0.5). 11and 14 (Ethoxy substituted at 7th position of 
benzopyran having isoxazoline and isoxazole ring with Br, CN with heterocyclic ring respectively). 8 and 13 
shows less inhibitory effect but can be considered positively. These compound posses isoxazole ring with 
same ethoxide at 7th position of benzopyran. So, it can be concluded that the benzopyran compounds having 
7ethoxy with isoxazole at aromatic part could be used positively against S. aureus (Fig. 4). When we screened 
our molecules 1-20 against Serratia sp.  strain, we found that compound 3 5 and 13  showed most promising 
inhibitory  effect . Compound 3 which is a formylated benzopyran, compound 5;a tertiary butyl group 
substituted isoxazole of 7 methoxy gem dichloro benzopyran  and compound 13;an ester derivative of gem 
dichloro 7-ethoxy benzopyran with an isoxazole moiety showing inhibition zones ranging between 13-15 mm 
indicating the presence of these groups or the pharmacophore is responsible for bacterial activity against this 
bacterial strain (Fig.4 ). According to our analysis report, it is seen that among all the testes compound 1-20, 
only 3, 5, 6, 8, 9, 13, 15 showed good inhibition against S.enteroccous strains with inhibition zones ranging 
between 9-14 mm. Compound 6 which has a ethoxy group at 7th position of benzopyran and methoxy 
attached to isoxazole with a benzene linker has maximum antibiotic effect. Next, to it 5, 8, 9, 13, 15, which all 
have ethoxy at 7th of benzopyran along with isoxazole are highly potent against this species. Compound 3 
which is a formylated benzopyran also show good inhibitory effect (Fig.4).The experimental results show that 
among all the tested compounds 1-20, Compound 6, 8 and 20 shows very good inhibitory effect against 
Acinetobacter with inhibition zones ranging between 14-16 mm. Compound 6 and 8 which consist of 
isoxazoles with 7-ethoxide of benzopyran shows significant inhibition against this species, but the interesting 
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observation is that 8 does not possess an aromatic linker which means aromatic linker is not at all responsible  
for bacterial activity. Another vital observation was that 20 which is a vicinal dichloro compound of 
benzopyran is equally potent as tetracycline (Fig.4). Compounds 1-20 presented no significant inhibition zones 
against  E. coli which gives us a strong affirmation that these classes of benzopyran isoxazoles compounds are 
totally beneficial for symbiotic bacteria. It is vague to give a single antibiotic against different types of bacterial 
infection. Still then if we look at the excel sheet graph of total antibacterial activity of the synthesized 
compound we can conclude that 3 and 6 can be good choice of treatment against various bacterial infections 
(Fig.4). 
    
 
Fig.4. A combined graphical representation of antibacterial activity of 20 compounds against all the 5 strains 
discussed above 
2.03.2.3. Minimum inhibitory Concentration (MIC) and Minimum bactericidal concentration (MBC) 
From the above analysis we draw a conclusion that the compounds like 3, 5, 6, 7, 8, 9, 11, 13, 14, 15, and 20 
shows appreciable antimicrobial effect. Hence we have chosen these compounds and proceeded for MIC and 
MBC studies. The results of the experiment is tabulated as follows (Table 2). 
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Table 2 MICs and MBCs expressed in µg/ml of the most active compounds against MDR resistance clinical 
isolates of bacterial strains 
Compound S.aureus Serratia S. enteroccous Acinetobactor 
MIC MBC MIC MBC MIC MBC MIC MBC 
3 1.95 3.90 1.95 3.90 3.90 7.85  
5  3.90 7.85 7.81 15.62 
6  3.90 7.85 
7  1.95 3.90 
8 3.90 7.85  1.95 3.90 1.95 3.90 
9  3.90 7.85  
11 1.95 3.90  
13 3.90 7.85 7.81 15.62 3.90 7.85 
14 1.95 3.90  
15  3.90 7.85 
20   1.95 3.90 
Tetracycline 0.5 0.8 1.2 2 1.87 3.75 1 2 
Gentamycin 0.46 0.93 1.87 3.75 0.93 1.87 3.75 7.50 
 
From the above study we conclude that for the most active compounds (3, 5, 6, 8, 9, 11, 13, 14, 15 and 20) of 
he series, the MIC and MBC were evaluated against their corresponding bacterial strains and the results are 
presented in table 3. All of these compounds showed good antibacterial effect with the MIC values ranges in 
between 1-8 µg /ml. All the compound assayed showed bactericidal activity with the MBC value in the ranges 
of 3-16 µg /ml. Compound 3 found to be most effective antibacterial candidate as well as bactericidal too. 
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2.03.2.4. Structure activity relationship 
  
Fig.5 Structure activity relationship of 16 compounds with respect to inhibition of 5 bacterial strains 
From the graphical analysis made from zone inhibition, MIC and MBC done above, some conclusions can be 
made regarding SAR are as follows 
Isoxazoles are very important for antibacterial activity when attached to aromatic part of benzopyran or 
flavones moiety but isoxazolines are less important as we have observed less inhibition in case of isoxazoline 
containing molecules 10, 16, 17, and 19 (Fig. 5). 
If F (Fig.5) is an alkyl group such as t-butyl or n-butyl activity increases (05) but if F= alkyl but D= OCH3 then 
there is a decrease in activity. So D also should be greater than methoxy group. (Fig.5). If F is a CN or Br like 
withdrawing group we have observed an increase in activity (11, 14, and 15).  
According to our experiment there is no requirement of a linker like benzene (E in Fig.5) as 13 shows an 
enhanced activity than others against four different strains of bacteria (Table 1). 
A & B if are Cl (Geminal dichloro) may increase the activity because some molecules possessing gem dichloro 
lack this activity but if vicinal dichloro is present (20 Table 1) C=Cl & B=Cl then a sharp increase in activity took 
place. But if a single Cl is attached C=Cl (2, 4 Table 1) there is a decrease in activity. 
Precursor of the isoxazole which is a formylated benzopyran shows an excellent activity even more than 
standard drugs (3 Table 1). Other starting compounds (1, 2, and 4) are not so effective. Hence our focus for 
the next study will be on 3 like starting molecules. 
2.04. Conclusion  
Our synthesized isoxazoles having dichloride (both geminal and vicinal) benzopyran shows a significant 
inhibitory effect against different strains of bacteria proved by in vitro antibacterial  assays such as zone of 
inhibition, MIC (1-8 µg /ml), MBC (3-16 µg /ml).  A comparison study of all the synthesized compounds was 
done with the help of Microsoft excels against 5 different strains. The graphical representation gave us an idea 
of a structure activity relationship. We have made detail SAR of all the molecules with relation to different 
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strains of bacteria. The vicinal dichloro isoxazole of benzopyran derivative is very much effective against 
S.aureus. Hence these chromene isoxazole scaffolds can act as good candidates against different class of 
bacterial infections after a clinical trial.   
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